Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. AstraZeneca PLC
  6. Summary
    AZN   US0463531089

ASTRAZENECA PLC

(AZN)
  Report
Delayed Nasdaq  -  04:00 2022-09-27 pm EDT
53.24 USD   +0.41%
10:00aBenevolentAI - Interim results for the six months ended 30 June 2022
AQ
05:44aAstraZeneca Says Bronchial Asthma Treatment Approved in Japan
MT
05:18aAstraZeneca-Merck's Rare Genetic Condition Medicine Gets Approval in Japan
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/21/2022 09/22/2022 09/23/2022 09/26/2022 09/27/2022 Date
56.44(c) 56.31(c) 54.58(c) 53.02(c) 53.24(c) Last
5 943 543 7 551 528 9 604 706 9 937 519 7 848 066 Volume
-1.67% -0.23% -3.07% -2.86% +0.41% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 44 322 M - -
Net income 2022 4 574 M - -
Net Debt 2022 24 523 M - -
P/E ratio 2022 37,8x
Yield 2022 2,77%
Sales 2023 46 914 M - -
Net income 2023 7 920 M - -
Net Debt 2023 20 650 M - -
P/E ratio 2023 21,4x
Yield 2023 2,88%
Capitalization 165 B 165 B -
EV / Sales 2022 4,28x
EV / Sales 2023 3,96x
Nbr of Employees 83 100
Free-Float 96,5%
More Financials
Company
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (97.7%). Net sales break down by treatment area between oncology (35.7%), cardiovascular, renal and metabolic diseases (21.9%), respiratory and autoimmune diseases (16.5%), and other (25.9%; inflammatory diseases, neurological diseases, gastrointestinal and infectious... 
Sector
Pharmaceuticals
Calendar
09/28Presentation
More about the company
Ratings of AstraZeneca PLC
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about ASTRAZENECA PLC
10:00aBenevolentAI - Interim results for the six months ended 30 June 2022
AQ
05:44aAstraZeneca Says Bronchial Asthma Treatment Approved in Japan
MT
05:18aAstraZeneca-Merck's Rare Genetic Condition Medicine Gets Approval in Japan
MT
04:02aBritish Drugmaker AstraZeneca Scores First-in-Class Approvals for Asthma, Rare Disease ..
MT
02:31aAstraZeneca Wins Japanese Approval For Treatment Of Neurofibromatosis Type 1 Genetic Co..
MT
02:17aAstraZeneca's Tezspire Approved In Japan For Treating Severe Asthma
MT
09/26In 4 Weeks Meet Pfizer, AstraZeneca, DiME & Many More at the Biosensors for Medical Wea..
AQ
09/26Astrazeneca Currently Down 10 Straight Days, on Track for Longest Losing Streak Since O..
DJ
09/26GSK plc - Iain Mackay, Chief Financial Officer, to retire from GSK, Julie Brown appoint..
AQ
09/26Ultomiris approved in Europe for the treatment of adults with generalised myasthenia gr..
AQ
09/26GSK Names Burberry Executive Julie Brown New Finance Chief
MT
09/26GSK PLC Names Julie Brown as New CFO; Iain Mackay to Retire in May
DJ
09/26GSK selects Burberry's Brown as its first female CFO
RE
09/26Valneva in talks with potential partner on second-gen COVID-19 vaccines
RE
09/26AstraZeneca Junks Ionis' Cholesterol Drug After Failing To Reach Efficacy Threshold In ..
MT
More news
News in other languages on ASTRAZENECA PLC
04:25aAstraZeneca : approbation de deux médicaments au Japon
04:02aLe fabricant britannique de médicaments AstraZeneca obtient des autorisations de premiè..
02:31aAstraZeneca obtient l'approbation japonaise pour le traitement de la maladie génétique ..
02:17aTezspire d'AstraZeneca approuvé au Japon pour le traitement de l'asthme sévère
09/26MIDDAY BRIEFING - Unternehmen und Märkte -2-
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
ETFs positioned on ASTRAZENECA PLCETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
VanEck Vectors Pharmaceutical ETF - USD5.25%-4.44%United_States
First Trust AlphaDEX European Dividend Inde...4.4%0.00%-Europe
IShares Nasdaq US Biotechnology - USD3.93%-4.38%United_States
Invesco Nasdaq Biotechnology ETF - USD3.8%-4.24%-United_States
IShares Nasdaq US Biotechnology (D) - USD3.8%-4.56%United_States
More ETFs positioned on ASTRAZENECA PLC
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Last Close Price 106,68 $
Average target price 141,77 $
Spread / Average Target 32,9%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC-8.98%166 556
JOHNSON & JOHNSON-3.58%435 655
ELI LILLY AND COMPANY11.32%292 179
ROCHE HOLDING AG-19.31%253 262
ABBVIE INC.4.29%249 673
PFIZER, INC.-25.33%245 989